Valneva (VALN) Competitors

Valneva logo
$5.65 -0.01 (-0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$5.52 -0.14 (-2.39%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VALN vs. SEPN, COAG, RXRX, SRPT, and TRAX

Should you buy Valneva stock or one of its competitors? Valneva's main competitors and comparable companies include Septerna (SEPN), Hemab Therapeutics (COAG), Recursion Pharmaceuticals (RXRX), Sarepta Therapeutics (SRPT), and First Tracks Biotherapeutics (TRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valneva compare to Septerna?

Septerna (NASDAQ:SEPN) and Valneva (NASDAQ:VALN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

11.4% of Valneva shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Septerna has a beta of 2.2, indicating that its stock price is 120% more volatile than the broader market. Comparatively, Valneva has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Septerna had 14 more articles in the media than Valneva. MarketBeat recorded 27 mentions for Septerna and 13 mentions for Valneva. Valneva's average media sentiment score of 0.61 beat Septerna's score of 0.11 indicating that Valneva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
4 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Valneva
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Septerna presently has a consensus target price of $56.44, suggesting a potential upside of 32.50%. Valneva has a consensus target price of $9.30, suggesting a potential upside of 64.31%. Given Valneva's higher probable upside, analysts plainly believe Valneva is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Septerna has higher earnings, but lower revenue than Valneva. Septerna is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$45.95M44.08-$48.88M-$1.29N/A
Valneva$197.56M2.73-$130.33M-$2.11N/A

Septerna has a net margin of -61.29% compared to Valneva's net margin of -110.33%. Septerna's return on equity of -14.98% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-61.29% -14.98% -10.03%
Valneva -110.33%-153.20%-39.50%

Summary

Septerna beats Valneva on 11 of the 17 factors compared between the two stocks.

How does Valneva compare to Hemab Therapeutics?

Valneva (NASDAQ:VALN) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Hemab Therapeutics had 1 more articles in the media than Valneva. MarketBeat recorded 14 mentions for Hemab Therapeutics and 13 mentions for Valneva. Valneva's average media sentiment score of 0.61 beat Hemab Therapeutics' score of 0.05 indicating that Valneva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valneva
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hemab Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

11.4% of Valneva shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hemab Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Hemab Therapeutics' return on equity of 0.00% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-110.33% -153.20% -39.50%
Hemab Therapeutics N/A N/A N/A

Valneva currently has a consensus price target of $9.30, indicating a potential upside of 64.31%. Hemab Therapeutics has a consensus price target of $56.00, indicating a potential upside of 37.05%. Given Valneva's higher probable upside, research analysts clearly believe Valneva is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Hemab Therapeutics has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$197.56M2.73-$130.33M-$2.11N/A
Hemab TherapeuticsN/AN/AN/A-$24.78N/A

Summary

Valneva and Hemab Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Valneva compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Valneva had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 13 mentions for Valneva and 6 mentions for Recursion Pharmaceuticals. Valneva's average media sentiment score of 0.61 beat Recursion Pharmaceuticals' score of 0.39 indicating that Valneva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Valneva
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Recursion Pharmaceuticals presently has a consensus target price of $8.18, suggesting a potential upside of 157.23%. Valneva has a consensus target price of $9.30, suggesting a potential upside of 64.31%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Valneva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Valneva has a net margin of -110.33% compared to Recursion Pharmaceuticals' net margin of -697.15%. Recursion Pharmaceuticals' return on equity of -47.85% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-697.15% -47.85% -36.26%
Valneva -110.33%-153.20%-39.50%

Recursion Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Valneva has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valneva has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$74.68M26.52-$644.76M-$0.90N/A
Valneva$197.56M2.73-$130.33M-$2.11N/A

Summary

Recursion Pharmaceuticals and Valneva tied by winning 8 of the 16 factors compared between the two stocks.

How does Valneva compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Valneva had 4 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 13 mentions for Valneva and 9 mentions for Sarepta Therapeutics. Valneva's average media sentiment score of 0.61 beat Sarepta Therapeutics' score of 0.58 indicating that Valneva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sarepta Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Valneva
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sarepta Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Valneva has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Sarepta Therapeutics has a net margin of -5.86% compared to Valneva's net margin of -110.33%. Sarepta Therapeutics' return on equity of -0.20% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-5.86% -0.20% -0.09%
Valneva -110.33%-153.20%-39.50%

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sarepta Therapeutics currently has a consensus price target of $23.67, suggesting a potential upside of 47.27%. Valneva has a consensus price target of $9.30, suggesting a potential upside of 64.31%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Valneva has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$2.20B0.78-$713.41M-$1.37N/A
Valneva$197.56M2.73-$130.33M-$2.11N/A

Summary

Sarepta Therapeutics and Valneva tied by winning 8 of the 16 factors compared between the two stocks.

How does Valneva compare to First Tracks Biotherapeutics?

Valneva (NASDAQ:VALN) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

First Tracks Biotherapeutics has lower revenue, but higher earnings than Valneva. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valneva$197.56M2.73-$130.33M-$2.11N/A
First Tracks BiotherapeuticsN/AN/AN/A-$2.79N/A

Valneva currently has a consensus target price of $9.30, indicating a potential upside of 64.31%. First Tracks Biotherapeutics has a consensus target price of $72.17, indicating a potential upside of 53.22%. Given Valneva's higher possible upside, analysts plainly believe Valneva is more favorable than First Tracks Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
First Tracks Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

In the previous week, Valneva had 11 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 13 mentions for Valneva and 2 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 1.46 beat Valneva's score of 0.61 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Valneva
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
First Tracks Biotherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

First Tracks Biotherapeutics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. First Tracks Biotherapeutics' return on equity of 0.00% beat Valneva's return on equity.

Company Net Margins Return on Equity Return on Assets
Valneva-110.33% -153.20% -39.50%
First Tracks Biotherapeutics N/A N/A N/A

11.4% of Valneva shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Valneva beats First Tracks Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VALN vs. The Competition

MetricValnevaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$548.29M$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-2.6826.5532.9127.39
Price / Sales2.7216.028.595.74
Price / CashN/A26.3721.9322.50
Price / Book4.064.074.403.70
Net Income-$130.33M-$22.86M$3.52B$392.17M
7 Day Performance-0.18%-7.26%-5.34%-4.53%
1 Month Performance0.71%-4.96%-3.61%-5.86%
1 Year Performance-37.57%-2.87%0.01%-7.78%

Valneva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VALN
Valneva
2.5954 of 5 stars
$5.65
-0.2%
$9.30
+64.6%
-37.5%$548.29M$197.56MN/A674
SEPN
Septerna
2.2538 of 5 stars
$43.70
+1.2%
$52.44
+20.0%
+83.1%$2.04B$98.88MN/A130
COAG
Hemab Therapeutics
2.6466 of 5 stars
$43.10
+4.7%
$54.71
+26.9%
N/A$2.01BN/AN/A59
RXRX
Recursion Pharmaceuticals
3.0046 of 5 stars
$3.68
-3.9%
$8.18
+122.3%
-23.2%$1.97B$53.94MN/A600
SRPT
Sarepta Therapeutics
3.5413 of 5 stars
$18.54
+1.2%
$22.88
+23.4%
-14.6%$1.96B$1.97BN/A835

Related Companies and Tools


This page (NASDAQ:VALN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners